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Epidemiological and clinical studies suggest that non-steroidal anti-inflammatory drugs
(NSAIDs), including cyclooxygenase (COX)-2 selective inhibitors, reduce the risk of devel-
oping cancer. Experimental studies in human cancer cell lines and rodent models of car-
cinogenesis support these observations by providing strong evidence for the antineoplastic
properties of NSAIDs. The involvement of COX-2 in tumorigenesis and its overexpression
in various cancer tissues suggest that inhibition of COX-2 is responsible for the chemo-
preventive efficacy of these agents. However, the precise mechanisms by which NSAIDs
exert their antiproliferative effects are still a matter of debate. Numerous other studies have
shown that NSAIDs can act through COX-independent mechanisms. This review provides
a detailed description of the major COX-independent molecular targets of NSAIDs and dis-
cusses how these targets may be involved in their anticancer effects. Toxicities resulting
from COX inhibition and the suppression of prostaglandin synthesis preclude the long-
term use of NSAIDs for cancer chemoprevention. Furthermore, chemopreventive efficacy
is incomplete and treatment often leads to the development of resistance. Identification
of alternative NSAID targets and elucidation of the biochemical processes by which they
inhibit tumor growth could lead to the development of safer and more efficacious drugs
for cancer chemoprevention.
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INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) are a diverse
class of drugs commonly used for the treatment of inflamma-
tory conditions, analgesia, and fever. Specific indications include
arthritis, headaches, menstrual cramps, and mild-to-moderate
pain from injuries. Figure 1 shows some of the most commonly
used NSAIDs and selective cyclooxygenase (COX)-2 inhibitors.
The pharmacological basis for the anti-inflammatory properties
of NSAIDs is attributed to inhibition of COX-1 and COX-2
enzymes that catalyze the conversion of arachidonic acid into
prostaglandin H2, a precursor for the synthesis of prostaglandins,
prostacyclins, and thromboxanes. These eicosanoids are known to
promote inflammation, pain, and fever (1). In addition, they pro-
vide protection for the lining of the stomach and intestines from
the damaging effects of acid, promote blood clotting by activating
blood platelets, and regulate kidney function. COX-1 is consti-
tutively expressed in many tissues and plays an important role in
tissue homeostasis, while COX-2 is induced by inflammatory stim-
uli and is generally believed to be more involved in pathological
processes (2). The prostaglandin synthesis pathway and its relation
to tumorigenesis are illustrated in Figure 2.
Epidemiological, clinical, and laboratory studies provide con-
vincing evidence that NSAIDs, including aspirin, non-aspirin
NSAIDs, and COX-2 selective inhibitors also have strong anti-
neoplastic properties. The chemopreventive efficacy of NSAIDs
against colorectal cancer (CRC) is particularly well-established.
For example, numerous population-based studies have shown that
regular, long-term users of NSAIDs have a significantly lower risk
of colorectal adenomatous polyps and CRC than non-users (3–
5). Clinical evidence of activity was first reported in case studies
by Waddell and Loughry in 1983 in which administration of the
NSAID sulindac (Clinoril®) was found to be associated with the
reduction of precancerous colorectal adenomas in patients with
Garner’s syndrome (6). Later, several clinical trials, including a
randomized trial conducted by Giardiello and colleagues reported
that sulindac can strongly inhibit the formation of adenomatous
polyps and cause regression of existing polyps in patients with
familial adenomatous polyposis (FAP) (7–10). Subsequently, the
COX-2 selective inhibitor, celecoxib (Celebrex®), was reported by
Steinbach and colleagues to inhibit adenoma formation in FAP
patients (11). This study led to the FDA approval of celecoxib for
the treatment of FAP in 1999, but was recently withdrawn for this
indication upon request by the manufacturer, Pfizer.
Although there are fewer epidemiological studies on can-
cers other than CRC, multiple studies demonstrate an associ-
ation between prolonged use of NSAIDs and lower incidence
of or deaths from cancers arising from diverse tissues. These
include tumors of breast (12–16), lung (12, 17), prostate (12,
18), bladder (12), ovaries (12, 19), esophagus (12), and stom-
ach (12). Epidemiological and clinical studies are supported by
evidence from numerous investigators reporting inhibitory effects
of NSAIDs on tumorigenesis in various rodent models, including
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FIGURE 1 | Chemical structures of common NSAIDs and selective
COX-2 inhibitors.
FIGURE 2 |The arachidonic acid cascade and cancer development. COX
enzymes catalyze the conversion of arachidonic acid into prostaglandin H2,
the precursor for all prostaglandins (PGs) and thromboxane A2 (TXA2). PGH2
is further converted into PGD2, PGE2, PGI2, PGF2α, and TXA2 by specific
synthases. These molecules mediate inflammation and are also involved in
gastrointestinal epithelium homeostasis, platelet activation, and kidney
function. Prostaglandins can also promote cell proliferation, angiogenesis,
metastasis, and inhibit apoptosis leading to tumor growth.
carcinogen-induced or transgenic models of colorectal, breast, and
other types of carcinogenesis (20, 21). Among the earliest reports
of the anticancer activity of NSAIDs were publications by Pollard
and Luckert who described inhibitory effects of indomethacin on
carcinogen-induced intestinal tumors (22, 23). Studies in cell cul-
ture models have been numerous as well and suggest that NSAIDs
have direct inhibitory effects on tumor cell growth and have been
especially useful for defining the underlying mechanism of action.
Unfortunately, suppression of prostaglandin synthesis from
COX-1 or COX-2 inhibition is associated with gastrointestinal,
renal, and cardiovascular toxicities that limit the dosage and long-
term use of NSAIDs for cancer chemoprevention. In addition,
currently available NSAIDs and COX-2 inhibitors do not com-
pletely protect all individuals from developing cancer. For example,
there have been reports of resistant adenomas and breakthrough
carcinomas during treatment with sulindac, which highlight the
limitations of currently available NSAIDs and COX-2 inhibitors
for chemoprevention (24). However, it is not clear if their efficacy
limitations are attributable to inherent mechanisms of drug resis-
tance or inability to achieve a sufficiently high dosage, given that
the anticancer activity appears to require high dosages adminis-
tered over extended periods of time, which increase the risk of
toxicity.
Evidence for the involvement of COX-2 in colorectal carcino-
genesis and its constitutive expression in multiple tumor types
has led researchers to postulate that inhibition of COX enzymes,
especially COX-2, is responsible for the chemopreventive efficacy
of NSAIDs and selective COX-2 inhibitors. Detailed reviews on
the role of COXs in tumorigenesis have been previously published
(5, 24, 25). However, other studies suggest that COX-independent
mechanisms may contribute to, or be fully responsible for their
anticancer properties. Identification of alternative targets and
additional biochemical processes involved in NSAID activity could
lead to the development of safer and more efficacious drugs for
cancer chemoprevention. This review examines the biochemical
processes associated with the antineoplastic effects of NSAIDs and
discusses their COX-independent mechanism of action. Detailed
mechanistic analyses that link reported direct non-COX targets
with the various cellular effects of this class of drugs are provided.
In addition, current and potential future approaches to develop
safer and more efficacious NSAID derivatives are outlined.
COX-INDEPENDENT MECHANISMS AND TARGETS
Numerous studies challenge the theory that COX inhibition is
solely responsible for the chemopreventive action of NSAIDs
by providing evidence that these effects can be exerted, at least
partially, through COX-independent mechanisms. For example,
in vitro studies have demonstrated that NSAIDs can inhibit pro-
liferation and/or induce apoptosis in multiple tumor cell lines
of different origins irrespective of their levels of COX-1 or
COX-2 expression (26–29). In addition, the growth-inhibitory
activity of NSAIDs cannot be reversed by supplementation with
prostaglandins, pointing to a mechanism that is independent
of suppressing prostaglandin production (30, 31). Furthermore,
there is often a significant discrepancy between the potency of a
particular NSAID to inhibit COX-1 and/or COX-2 and its potency
to inhibit tumor cell growth in vitro and in vivo. This is high-
lighted in Table 1, which shows that various chemical families of
NSAIDs display appreciably different potencies to inhibit tumor
cell growth, yet there is no correlation between their potency
to inhibit growth and potency to inhibit COX-1 or COX-2. For
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Table 1 | Potency of a panel of NSAIDs to inhibit colon tumor cell
growth and cyclooxygenases.
NSAID Growth
IC501
COX-1
IC502
COX-2
IC502
Serum levels
(µM)3
Celecoxib 50 >30 2.25 2
Sulindac sulfide 60 1.02 10.4 15
Diclofenac 160 0.14 0.05 6
Indomethacin 180 0.16 0.46 1.4
Piroxicam 900 0.76 8.9 17
Ibuprofen 975 4.75 >30 40
Flurbiprofen 1800 0.44 6.42 53
Aspirin 5000 4.5 13.9 10
1HT-29 human colon tumor cells, 72 h MTS assay (184). 2Whole blood COX assays
(32). 3From therapeutic dosages (185).
example, the non-selective COX inhibitor indomethacin has much
lower antiproliferative activity compared with sulindac sulfide
despite having a similar chemical scaffold and an approximately
10-fold lower IC50 to inhibit both COX-1 and COX-2 in whole
blood COX assays (32). Similarly, while selective COX-2 inhibitors
celecoxib and rofecoxib inhibit COX-2 with similar IC50 val-
ues, celecoxib has much higher antiproliferative activity in both
COX-2-positive and COX-2-negative cell lines (33). Other stud-
ies confirm these findings through the use of genetic methods by
showing that: (1) tumor cells in which expression of COX-2 has
been knocked down by antisense cDNA do not display increased
apoptosis but remain sensitive to COX-2 inhibitors, (2) the level
of knockdown does not affect sensitivity to COX inhibitors,
and (3) fibroblasts from COX-1−/−, COX-2−/−, or COX-1/2−/−
knockout mice retain sensitivity to various NSAIDs (34–36).
In general, the concentration of a given NSAID or selec-
tive COX-2 inhibitor required to inhibit tumor cell proliferation
in vitro is much higher than that required to inhibit COX-1 and/or
COX-2 activity (37). This is an important consideration since
experimental studies in rodent models, as well as clinical stud-
ies typically demonstrate chemopreventive efficacy of NSAIDs
only at doses higher than those necessary for anti-inflammatory
effects. For example, Reddy et al. showed that doses of celecoxib
required to decrease incidence and multiplicity of aberrant crypt
foci (ACF) in the azoxymethane (AOM)-induced mouse carcino-
genesis model reached plasma concentrations of approximately
9µmol/L, while plasma concentrations of 1.3µmol/L were suffi-
cient to inhibit adjuvant-induced arthritis (38). Lower doses that
reached around 1.8µmol/L plasma concentrations did not have
an effect on ACF development (39). In a randomized, placebo-
controlled clinical trial, Steinbach et al. reported that celecoxib
caused a significant reduction in colorectal polyp burden in FAP
patients at a dose of 800 mg/day but not at the standard anti-
inflammatory dose of 200 mg/day bid (11). Additional in vivo
evidence for COX-independent mechanisms of NSAID chemo-
prevention is provided by a study in the APCMin/+mouse model of
colorectal carcinogenesis. Administration of sulindac dramatically
reduced the number of tumors in Min without altering eicosanoid
formation (40). Also, increasing the levels of prostaglandin E2 and
leukotriene B4 by dietary arachidonic acid supplementation did
FIGURE 3 | Metabolism of sulindac. Prodrug sulindac undergoes
reversible reduction into the active sulfide form through the action of liver
enzymes and colonic bacteria. Sulindac sulfide is a non-selective COX
inhibitor and is responsible for the anti-inflammatory properties of sulindac.
The sulfone metabolite is generated by irreversible oxidation of the sulfoxide
in the liver, and does not have anti-inflammatory activity. Both sulindac
sulfide and sulindac sulfone have antineoplastic activity in vitro and in vivo.
not affect tumor number or size. It has to be noted, however,
that prostaglandin levels are decreased in the colorectal mucosa
of FAP patients with adenoma regression on sulindac (41, 42).
These results may explain the modest chemopreventive efficacy
of currently available NSAIDs such as sulindac or celecoxib at the
anti-inflammatory dosages and highlight the need for more potent
and selective inhibitors.
Perhaps the most compelling evidence that COX-independent
mechanisms exist comes from studies showing that NSAID
metabolites or derivatives that lack COX-inhibitory activity can
retain or have improved antitumor activity. Sulindac sulfone
(exisulind) is a prototypical example of a non-COX-inhibitory
NSAID derivative with in vitro and in vivo anticancer activity
(43–49). As shown in Figure 3, sulindac is a prodrug that under-
goes reversible reduction into the active sulfide form through the
action of liver enzymes and colonic bacteria (50). Sulindac sul-
fide is a non-selective COX inhibitor and is responsible for the
anti-inflammatory properties of sulindac. The sulfone metabo-
lite is generated by irreversible oxidation of the sulfoxide in the
liver, and does not have anti-inflammatory activity. Numerous
studies have shown that sulindac sulfone can inhibit tumor cell
growth and induce apoptosis in multiple tumor types despite lack-
ing COX-1 and COX-2 inhibition. Furthermore, sulindac sulfone
was shown to effectively inhibit carcinogen-induced tumorigene-
sis of the colon, mammary glands, lung, and bladder (43–46, 48,
51, 52). In studies involving the AOM model of rat colon tumori-
genesis, sulindac sulfone did not reduce prostaglandin levels in
the colon mucosa and was able to reach plasma concentrations
above those required to inhibit tumor cell growth and induce
apoptosis in vitro (Table 2). In clinical trials, sulindac sulfone
(exisulind, Aptosyn®) caused significant regression of polyps in
patients with familial (53) or sporadic (54) adenomatous polypo-
sis. Unfortunately, exisulind did not receive FDA approval because
of hepatotoxicity, which also limited the dosage.
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Table 2 | Inhibition of azoxymethane-induced colon tumorigenesis in
rats by sulindac sulfone and sulindac (44).
Treatment Dose
(ppm)
Tumor
burden#
PGE2 levels
(% control)
Serum sulfone
(µM)
Control 0 10.5 100 –
Sulfone 500 6.9 94.5 247
Sulfone 1000 3.3* 105 346
Sulfone 2000 1.9* 79 392
Sulindac 400 1.9* 39.5* 121
*p<0.05, #sum of sizes of adenomas and adenocarcinomas.
Additional evidence to suggest that COX inhibition is not
required for the chemopreventive effects of NSAIDs is provided by
studies of NSAIDs with a chiral center that exist as a racemic mix-
ture of S- and R-enantiomers. The S-ibuprofen and S-flurbiprofen
are non-selective COX inhibitors and have antiproliferative activ-
ity (55, 56). However, R-ibuprofen and R-flurbiprofen, which lack
COX-1 or COX-2 enzyme activity, also inhibit tumor cell growth
in vitro, in xenograft mouse models of human tumors, and in
transgenic mouse models of tumorigenesis (56–58). Similarly, the
R-enantiomer of etodolac, devoid of COX inhibition, has been
shown to inhibit colorectal carcinogenesis and induce cytotoxi-
city in multiple myeloma cells (59, 60). It is important to note
that about 50% of R-ibuprofen is converted to the S-enantiomer
in vivo although the antiproliferative activity does not corre-
late with COX-2 expression. Synthetic NSAID analogs in which
COX-inhibitory activity has been designed-out but retain anti-
cancer activity provide further proof for the existence of COX-
independent mechanisms. The sulindac derivatives, SSA and SBA,
aspirin derivative, NCX-4016, and celecoxib derivatives, OSU-
03012 and dimethyl-celecoxib (DMC), represent some of the
non-COX-inhibitory NSAID analogs that display equal or higher
antitumor efficacy compared to the parent drug (61–64).
Taken together, these studies provide a strong case that mech-
anisms independent of COX-1 and/or COX-2 inhibition fully or
partially contribute to the chemopreventive activity of traditional
NSAIDs and selective COX-2 inhibitors. The anticancer effects of
this class of compounds have been proposed to consist of mul-
tiple cellular mechanisms, which include induction of apoptosis,
inhibition of proliferation and angiogenesis, and more recently,
induction of autophagy. A detailed mechanistic analysis of how
currently known direct NSAID targets can lead to these biochem-
ical effects is discussed below. These targets are summarized in
Table 3.
INDUCTION OF APOPTOSIS
It is now widely accepted that apoptosis is the primary mech-
anism responsible for the antineoplastic properties of NSAIDs,
which was first reported to occur in cancer cells treated with
sulindac sulfide by two different groups in 1995 (45, 65). The COX-
independent activity of sulindac sulfide was evident by the ability
of sulindac sulfone to also induce apoptosis (44, 45). The phar-
macological relevance of this effect was demonstrated by studies
reporting that treatment with sulindac can stimulate apoptosis
in the normal rectal mucosa of FAP patients (66, 67), normal
intestinal mucosa of APCMin/+ mice (68), and in the colorectal
carcinomas of carcinogen-treated rats (69, 70). Interestingly, the
non-COX-inhibitory sulindac sulfone was found to induce apop-
tosis selectively in rectal polyps of FAP patients but not in normal
rectal mucosa, which implies an aspect of selectivity not appar-
ent with conventional chemotherapeutic drugs that also act by
inducing apoptosis (53). Consistent evidence from in vitro studies
also demonstrates that traditional NSAIDs and COX-2 selective
inhibitors, as well as their non-COX-inhibitory derivatives can
induce apoptosis in various cancer cell lines (2, 5, 45). Many
mechanisms and targets have been proposed to mediate apopto-
sis induced by NSAID treatment. While a particular NSAID may
have its own, more or less specific, COX-independent target, it
is generally recognized that a combination of effects on multiple
pathways through direct and indirect targets is responsible for the
apoptosis-inducing properties of NSAIDs. Major direct cellular
targets that have been shown to mediate apoptosis induction by
NSAIDs are discussed below.
cGMP PHOSPHODIESTERASES
A direct molecular target for sulindac, celecoxib, and potentially
other non-aspirin NSAIDs is the cyclic guanosine monophos-
phate phosphodiesterases (cGMP PDEs). PDEs are a large family
of enzymes that catalyze the hydrolysis of cAMP or cGMP to
biologically inactive 5′-nucleoside monophosphates. Previously,
it was shown by Piazza and colleagues that sulindac sulfone can
inhibit certain cGMP-degrading isozymes, causing an increase in
intracellular cyclic GMP levels, thus activating cGMP-dependent
protein kinase (PKG), which in turn activates pathways that lead
to apoptosis (46, 71). Importantly, a series of sulindac sulfone
analogs with improved cGMP PDE inhibitory activity were syn-
thesized and a positive correlation was established between the
rank order of potency for PDE inhibition, apoptosis induction,
and growth inhibition in colon cancer cell lines (71). More recent
studies have shown that sulindac sulfide can also directly bind
and inhibit the cGMP-specific PDE5 in recombinant enzyme
assays at concentrations lower than its IC50 for growth inhibi-
tion (61). Although sulindac sulfide was found to have activ-
ity against other PDE isozymes, including PDE2, PDE3, and
PDE10, sulindac sulfide displayed significantly higher selectiv-
ity toward PDE5 inhibition. In addition, PDE5 was found to be
overexpressed in various cancer cell lines compared with normal
primary epithelial cells. PDE5 appears to be a major cGMP-
hydrolyzing enzyme in tumor cells as indicated by the ability of
sulindac sulfide to inhibit cGMP-hydrolysis in whole cell lysates
and increase intracellular cGMP levels in intact cells. This effect
appears to be selective for tumor cells, given that sulindac sul-
fide more effectively inhibits cGMP PDE activity and induces
apoptosis in colon and breast tumor cell lines compared with
normal human mammary epithelial cells (HMEC) or colono-
cytes from normal human colon mucosa (NCM460) (61, 72,
135). Transfecting tumor cell lines with PDE5 siRNA alone was
recently found to be sufficient to induce apoptosis and inhibit
tumor cell growth (73). Together, these results provide evidence
that apoptosis induction by sulindac sulfide is mediated through
PDE5 inhibition and the elevation of intracellular cGMP levels.
Nonetheless, the contribution of additional PDE isozymes cannot
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Table 3 | Cyclooxygenase-independent direct cellular targets of NSAIDs and metabolites.
Sulindac Sulindac
sulfide
Sulindac
sulfone
Celecoxib Valdecoxib Aspirin Salicylate Indomethacin R -etodolac Reference
COX
COX-1 – X – – – X – X –
COX-2 – X – X X X – X –
COX-INDEPENDENTTARGETS
PDE5 X X X Thompson et al. (71),
Tinsley et al. (61),
Tinsley et al. (72), Klein
et al. (75)
PPARγ X Lehmann et al. (88)
PPARδ X X He et al. (92)
RXRα X X Kolluri et al. (98), Zhou
et al. (100)
IKKβ X X X Yamamoto et al. (104),
Yin et al. (106)
PDK-1 X Zhu et al. (111), Arico et
al. (112), Kulp et al. (113)
SERCA X X Johnson et al. (117),
White et al. (123)
CA IX/XII X X Weber et al. (128), Di
Fiore et al. (129)
Sp1 X Wei et al. (157)
AMPK X Hawley et al. (168)
be ruled out, given that conventional PDE5 inhibitors, such as
sildenafil, do not display significant potency to inhibit tumor cell
growth.
Further testing with a diverse group of other NSAIDs also
demonstrated a strong correlation between their ability to inhibit
cGMP PDE in lysates from HT-29 colon tumor cells and their
growth-inhibitory activity, suggesting that cGMP-specific PDEs
could be cellular targets for other NSAIDs as well (72). Indeed,
structurally diverse NSAIDs such as celecoxib, indomethacin, and
meclofenamic acid were shown to inhibit cGMP PDE activity and
increase intracellular cGMP levels in SW480 colon cancer cells
(74). Among these, celecoxib was shown to directly inhibit recom-
binant PDE5 enzyme activity (75), whereas the specific cGMP
PDE isozymes that other NSAIDs may bind remains unknown.
Interestingly, the COX-2 inhibitor rofecoxib (Vioxx®) that was
withdrawn from the market because of cardiovascular toxicity
and for which anticancer activity has not been well reported,
lacks PDE5 inhibitory activity (74). Given that conventional PDE5
inhibitors are being studied for cardioprotective benefits, it is pos-
sible that the PDE5 inhibitory activity of celecoxib may reduce
its potential for cardiovascular toxicity (76, 77). Consistent with
this possibility, sulindac has been previously reported to have car-
dioprotective benefits in experimental models, despite its COX-2
inhibitory activity (78).
Activation of PKG alone is sufficient to induce apoptosis in
colon cancer cells (79) and PKG activation has been shown to
occur after treatment with sulindac sulfide, sulfone, and celecoxib
(61, 74, 80). One mechanism that activation of PKG can lead to
apoptosis in tumor cells is through the suppression of canonical
Wnt/β-catenin signaling. We and others have shown that both
sulindac sulfide and sulfone can reduce nuclear β-catenin lev-
els, thereby inhibiting Tcf/Lef-mediated transcriptional activity
(73). Celecoxib has also been shown to reduce total β-catenin lev-
els and inhibit the DNA-binding ability of the β-catenin/Tcf-Lef
complex, although it is unable to decrease nuclear β-catenin lev-
els (81). By contrast, neither rofecoxib nor R-flurbiprofen were
found to affect β-catenin expression or nuclear localization. The
latter compounds are also unable to increase intracellular cGMP
levels and activate PKG, pointing to a mechanistic link between
cGMP PDE inhibition and inhibition of Wnt signaling that is
independent of COX binding. PKG can directly phosphorylate
β-catenin in cell-free assays presumably marking it for protea-
somal degradation in an APC and GSK3β-independent manner
(71). Consistently, sulindac sulfide, sulfone, and celecoxib appear
to increase the proteasomal and caspase-dependent degradation
of β-catenin (71, 81, 82). In addition, PKG has been shown to
attenuate β-catenin mRNA levels by suppressing transcription
from the CTNNB1 gene (83). Indeed, recent results from our lab
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FIGURE 4 | Mechanistic model for the antineoplastic properties of
sulindac. Inhibition of PDE5 and potentially other PDE isozymes by sulindac
metabolites leads to an elevation of intracellular cGMP levels activating
protein kinase G. PKG activation can lead to the induction of apoptosis, and
inhibition of proliferation and angiogenesis through activation of JNK1 and
downregulation of β-catenin-mediated transcription.
clearly demonstrate that sulindac sulfide can potently inhibit tran-
scription from the CTNNB1 promoter in colon cancer cell lines
resulting in reducedβ-catenin mRNA levels. Consistent with PDE5
being a target for these NSAIDs, knockdown of PDE5, by itself, is
able to reduce nuclear β-catenin levels and induce apoptosis in
breast and colon cancer cell lines (73). These effects were mim-
icked by use of specific PKG activators such as 8-Br-cGMP and
other known PDE5 inhibitors, and are accompanied by reduced
levels of anti-apoptotic and pro-proliferative proteins regulated by
β-catenin such as survivin and cyclin D1.
An additional mechanism that may mediate the pro-apoptotic
effects of PKG is the activation of c-Jun N-terminal kinase 1
(JNK1). PKG can activate JNK1 through phosphorylation of
MEKK1 and JNK1 activity and has been shown to be necessary
for apoptosis induction by sulindac and sulindac sulfone, in vitro
and in vivo (84). The exact pathway may involve direct phos-
phorylation and inactivation of anti-apoptotic proteins, Bcl-2 and
Bcl-XL by JNK1, and the expression of pro-apoptotic proteins
such as Bim or Bad through JNK1-mediated activation of tran-
scription factors (85). In addition, JNK1 has been shown to be
necessary for sequestration of β-catenin by FOX04 in the cyto-
plasm induced by PKG activation (83). These results indicate that
inhibition of cGMP PDEs by NSAIDs have the potential to restore
APC tumor-suppressor function in colorectal, breast, and poten-
tially other cancer types by attenuating oncogenic Wnt signaling,
thereby leading to apoptosis induction. In this respect, PDE5 and
possibly other cGMP PDEs represent attractive targets for cancer
chemoprevention and/or therapy. A mechanistic model for the
induction of apoptosis by cGMP PDE inhibition is provided in
Figure 4.
PPARα, γ, AND δ
The peroxisome proliferator-activated receptors are a class of
nuclear hormone receptors that regulate proliferation, differentia-
tion,apoptosis, and inflammation by modulating the transcription
of a variety of target genes (86). Three isoforms have been identi-
fied, PPARα, γ, and δ, all of which bind to specific DNA sequences
as heterodimers with the retinoid acid X receptors (RXRs). Loss
of PPARγ is implicated in colorectal carcinogenesis, while ligands
for PPARγ can suppress breast carcinogenesis in experimental ani-
mal models and inhibit anchorage-dependent cell growth in colon
cancer cell lines (87). NSAIDs indomethacin (100µM), ibuprofen
(100µM), fenoprofen (100µM), and flufenomic acid (100µM)
can activate PPARα and γ in monkey kidney epithelial cells trans-
fected with a PPARγpromoter reporter construct (88). In addition,
sulindac sulfide (100µM) significantly induces PPARγ promoter
activity in non-small cell lung cancer (NSCLC) cells, A549 and
H2122 leading to increased E-cadherin expression and decreased
colony formation in soft agar assays (89). Among these NSAIDs,
indomethacin can directly bind purified PPARγ and effectively
compete with known PPARγ ligands in cell-free assays. Therefore,
it is likely that other NSAIDs are direct ligands for PPARγ as well,
although this possibility currently remains untested.
PPARδ, contrary to other PPARs previously described, is a
growth promoting protein that is activated by the COX-2 derived
prostaglandin, prostacyclin (PGI2), and is often overexpressed
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in colon cancer cells (90, 91). PPARδ expression is negatively
regulated by the APC tumor-suppressor pathway through the
β-catenin/TCF-lef responsive elements in its promoter (92). As
shown by He et al. sulindac sulfide (200µM) and indomethacin
(400µM) can bind and repress PPARδ transcriptional activity in
HCT116 and SW480 human colon cancer cells (92). In addition,
overexpression of PPARδ can partially block apoptosis induc-
tion after NSAID treatment. Although the authors show that
sulindac and indomethacin disrupt the DNA-binding ability of
PPARδ/RXR heterodimers leading to inhibition of transcription, it
is also possible that a decrease in nuclearβ-catenin via cGMP phos-
phodiesterase inhibition contributes to these effects by directly
downregulating PPARδ levels. More recent studies by Liou et al.
provide evidence that 14-3-3ε, a downstream target of PPARδ, is
responsible for its anti-apoptotic effects, and is effectively down-
regulated by sulindac sulfide, sulfone, and indomethacin treatment
in colon cancer cells (93). Overexpression of PPARδ can prevent
the reduction in 14-3-3ε levels and confer apoptosis resistance,
while overexpression of 14-3-3ε alone was found to be sufficient to
significantly reduce apoptosis levels after NSAID treatment. These
findings demonstrate the importance of PPARδ and 14-3-3ε as
effectors of NSAID-mediated apoptosis and validate their poten-
tial as novel targets for cancer prevention and therapy. Further-
more, decreased PPARδ activity cannot be explained by reduced
prostacyclin production since these effects are observed in tumor
cell lines irrespective of their level of COX-2 expression and also
after treatment with the non-COX-inhibitory sulindac sulfone.
Novel analogs of sulindac that lack COX inhibition but can activate
PPARγ have also been characterized (94).
RETINOIC X RECEPTOR-α
Retinoid RXRs are members of the nuclear receptor superfam-
ily involved in controlling many biological processes including
carcinogenesis. There are three subtypes of RXR receptors, α,
β, and γ, which upon ligand binding heterodimerize with other
nuclear receptors such as retinoic acid receptor (RAR), PPARs,
liver X receptor (LXR) among others, resulting in DNA-binding
and transcriptional activation (95). The relevance of RXRα in can-
cer is well-established as genetic disruption of RXRα can promote
tumorigenesis (96) and RXRα binding to PML/RAR is necessary
for the development of acute promyelocytic leukemia (97). The
R-enantiomer of etodolac, which lacks COX-inhibitory activity,
has been shown to bind RXRα and selectively induce apopto-
sis in tumor cell lines (98). In cancer cells, a truncated RXRα
(tRXRα) that results from incomplete proteolytic processing of
RXRα also exists, and can act non-genomically through interaction
with other proteins to drive tumor cell survival and proliferation
(99). More recently, sulindac sulfide was demonstrated to specifi-
cally bind tRXRα and inhibit its interaction with the p85α subunit
of phosphotidlyinositol-3-kinase (PI3K) (100). This resulted in
suppression of downstream Akt signaling and induction of apop-
tosis across a diverse set of tumor cell lines. A novel derivative
of sulindac sulfide devoid of COX-inhibitory activity but with
improved potency to bind RXRα (K-80003) was synthesized and
shown to have significant antitumor activity in vitro and in vivo.
These effects were significantly attenuated by siRNA knockdown
of RXRα indicating that RXRα is a direct target of sulindac, but
significantly enhanced by TNFα treatment that was shown to con-
vert Akt signaling to an RXRα-dependent manner in cancer cells.
Overall, these findings suggest that RXRα-mediated apoptosis
induction contributes to the chemopreventive effects of sulindac,
etodolac, and potentially other NSAIDs. The feasibility of targeting
RXRα for cancer therapy has already been demonstrated by Tar-
gretin, a synthetic RXR ligand, currently in use for the treatment
of cutaneous T-cell lymphoma (101).
IKKβ/NF-κB
Numerous studies provide evidence that NSAIDs may exert their
apoptotic effects by directly modulating NF-κB signaling. NF-κB
transcription factor, composed of p50 and p65 (Rel A) subunits,
is retained in the cytoplasm in its inactive form when complexed
with the inhibitory regulatory protein IκB. Phosphorylation of
IκB by the PKG IKKβ leads to its ubiquitination and proteasomal
degradation leaving free NF-κB to enter nucleus and bind DNA,
resulting in transcriptional activation (102, 103). NF-κB mediates
its anti-apoptotic effects by activating cellular inhibitors of apop-
tosis such as TRAF1/2 and c-IAP1/2, or promoters of cell survival
such as c-myc. Aspirin (5 mM), sodium salicylate (5 mM), sulindac
(1 mM), and its metabolites sulindac sulfide (200µM) and sulfone
(1 mM) can inhibit NF-κB-dependent transcriptional activity in
COS cells transfected with an NF-κB-responsive expression vector
(104). Furthermore, both S- and R-enantiomers of flurbiprofen
(1 mM), as well as ibuprofen (2 mM) were shown to inhibit NF-κB
activity in macrophage and prostate cancer cell lines, respectively
(105). Notably, these concentrations are comparable to concen-
trations required to induce apoptosis in tumor cell lines and
the activity of non-COX derivatives such as sulindac sulfone and
R-flurbiprofen points to a COX-independent effect. Aspirin, sal-
icylate, and sulindac can directly bind and inhibit recombinant
IKKβ, the upstream positive regulator of NF-κB (104). In addition,
aspirin and salicylate were shown to be potent ATP-competitive
inhibitors of this enzyme with IC50 values of about 50µM (106).
Therefore, it is likely that inhibition of NF-κB signaling by var-
ious NSAIDs also involves direct binding to IKKβ. Consistently,
sulindac sulfide and sulfone can inhibit IKKβ enzyme activity in
COS cells (104) while celecoxib was found to suppress cigarette
smoke condensate-induced NF-κB activation by inhibiting IKKβ
phosphorylation in NSCLC cell lines (107).
Dysregulation of NF-κB signaling through mutations in NF-
κB itself or in regulatory proteins such as IκB is detected in many
tumor types making these proteins attractive targets. However, in
some cell types, NF-κB has also been shown to activate apopto-
sis through a non-canonical pathway. For example, contrary to
its effects on NSCLC cells, treatment of cervical cancer cells with
celecoxib results in increased NF-κB DNA-binding and apoptosis
(108). This discrepancy needs to be addressed when considering
targeting this pathway with inhibitors.
PDK-1/Akt
A direct cellular target for celecoxib is the 3-phosphoinositide-
dependent kinase-1 (PDK-1). PDK-1 incorporates growth sig-
naling from upstream PI3K by phosphorylating and activating
protein kinase B (PKB/Akt), a critical regulator of cellular pro-
liferation and survival. In many tumors, particularly with PTEN
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deletions, the PI3K/PDK-1/Akt pathway is constitutively activated
promoting tumor growth. Akt exerts some of its anti-apoptotic
effects by phosphorylating and inactivating the pro-apoptotic pro-
tein BAD, stabilizing β-catenin levels by direct phosphorylation
and inactivation of GSK3β or by phosphorylating caspase-9 to
prevent its cleavage into active caspase-9, among others (109,
110). Many studies have reported that induction of apopto-
sis by celecoxib is associated with inhibition of PDK-1 and its
downstream target Akt (111–113). In cell-free assays, celecoxib
can inhibit recombinant PDK-1 in an ATP-competitive manner
(IC50= 48µM). The importance of these targets for apoptosis
induction appears to be dependent on mutational or expres-
sional status of these kinases, as overexpression of PDK-1 but
not Akt can confer resistance to celecoxib-induced apoptosis in
HT-29 colon cells (112), whereas overexpression of either one
of these kinases produces a marginal rescue in viability in PC-3
prostate cancer cells (111). Furthermore, HT-29 cells expressing a
kinase-defective PDK-1 remained sensitive to celecoxib. Moreover,
inhibition of Akt phosphorylation, the primary target of PDK-1,
is not consistently observed across all tumor cell lines even though
apoptosis induction is comparable after celecoxib treatment (114,
115).
Although these findings raise questions about the involve-
ment of PDK-1 in celecoxib-induced apoptosis, structurally sim-
ilar analogs that are more potent inhibitors of PDK-1 but that
lack COX-2 inhibition, such as OSU-03012 (111) and DMC
(116), have improved apoptosis-inducing and growth-inhibitory
activities, implicating PDK-1 in the pro-apoptotic effects of cele-
coxib. Given the importance of PDK-1/Akt signaling in tumor
growth, these compounds represent promising leads that can
be exploited for the development of safer and more efficacious
derivatives.
SARCOPLASMIC/ER CA+2 ATPase
Sarcoplasmic/ER Ca+2 ATPase (SERCA) is a transmembrane
endoplasmic reticulum (ER) protein that maintains the Ca+2
gradient between the cytosol and the ER. Celecoxib can directly
inhibit SERCA activity (IC50= 35µM) in PC-3 human prostate
cancer cells, thereby preventing Ca+2 reuptake into the ER and
leading to elevated free intracellular Ca+2 concentrations (117).
It was demonstrated, through the use of microsome and plasma
membrane preparations from PC-3 cells, that celecoxib specifi-
cally inhibits the ER Ca+2 ATPase while exerting no inhibition
on the plasma membrane Ca+2 ATPase. Intriguingly, this activity
was found to be highly specific for celecoxib and was not observed
with other NSAIDs including rofecoxib. A number of subsequent
studies eventually established that calcium release from the ER is
a rapid and potent effect of celecoxib treatment, resulting in the
activation of the ER stress response (ESR) (118, 119). The pri-
mary purpose of ESR induction is to alleviate the effects of the
particular cellular insult and maintain ER homeostasis. However,
in conditions of persistent disturbance, such as continued calcium
leakage with celecoxib treatment, ESR has been shown to medi-
ate cell death by triggering apoptosis. As a consequence, typical
features of ESR can be observed in celecoxib-treated cells. These
include global repression of protein translation indicated by phos-
phorylation and inactivation of eukaryotic translation initiation
factor 2α, but strong induction of proteins that mediate ESR such
as glucose regulated protein molecular weight 78 (GRP78) and
CHOP (CCAAT/enhancer binding protein homologous transcrip-
tion factor) (120–122). Importantly, ESR-inducing activity is also
displayed by the non-COX-inhibitory DMC derivative of cele-
coxib (119). In this study, ESR activation was observed in mouse
xenograft tumors after celecoxib and DMC administration, under-
scoring the in vivo relevance of this pathway in celecoxib-induced
apoptosis.
A more recent study has shown that sulindac sulfide can
also bind SERCA in a similar fashion to celecoxib, albeit with
lower potency (123). This inhibition was associated with eleva-
tion of cytosolic Ca+2, induction of GRP78, and activation of
ER-associated caspase-4 in glioma cell lines. The potency of cele-
coxib and sulindac sulfide to induce GRP78 correlated with their
potency to inhibit glioma cell growth suggesting that ESR activa-
tion is involved in their glucotoxicity. Finally, it is worthwhile to
further note that sustained elevation of cytosolic Ca+2 levels can
directly initiate apoptosis irrespective of ESR owing to the critical
role of Ca+2 in regulating mitochondrial permeability transition
pores and Ca+2-sensitive endonucleases, proteases, and caspases.
CARBONIC ANHYDRASES
Carbonic anhydrases (CAs) are a large family of zinc metalloen-
zymes that catalyze the reversible interconversion of carbon diox-
ide and bicarbonate, thereby regulating acid-base balance in blood
and other tissues. At least 12 isoforms have been identified, some
of which are cytosolic and others are membrane-bound. Many
tumor cells express membrane-bound CAs IX and XII, that are
under the transcriptional control of hypoxia-inducible factor-1
(Hif-1) (124). These CAs were shown to promote tumor growth
by counteracting acidosis under hypoxic conditions (125, 126).
Furthermore, their expression levels correlate with tumor aggres-
siveness and an extremely poor prognosis (127). Celecoxib, by
virtue of its sulfonamide moiety, can bind to the catalytic zinc of
CAs and potently inhibit a number of these enzymes (CAs I, II,
IV, IX, and XII) in the low nanomolar range (128). The IC50 of
celecoxib against tumor-associated CAs IX and XII are reported
to be 16 and 18 nM respectively (129), values significantly lower
than its IC50 for COX-2 inhibition (40 nM) (130). These studies
also demonstrate that valdecoxib can inhibit these enzymes with
comparable potency, whereas rofecoxib, which contains a methyl
sulfone group, does not inhibit CA activity.
These findings suggest that celecoxib could induce apoptosis in
tumor cells through a mechanism that involves preventing hypoxic
adaptation ultimately resulting in reduced intracellular pH and
impaired cellular metabolism. Although a number of studies pro-
vide strong evidence through use of genetic knockdown methods
for the involvement of CAs IX and XII in tumor growth, studies
directly implicating these enzymes in celecoxib-induced apoptosis
are still lacking. However, several specific CA inhibitors such as
acetazolamide, methazolamide, or ethoxzolamide previously have
been demonstrated to have significant antitumor efficacy in mul-
tiple in vitro and in vivo models (131), highlighting the need for
future studies aimed at determining whether these enzymes rep-
resent valid non-COX targets of celecoxib that contribute to its
pro-apoptotic properties.
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INHIBITION OF PROLIFERATION
Unlike their well-defined ability to induce apoptosis, inhibition of
proliferation by NSAID treatment is primarily observed in vitro or
in experimental animal models. Notably, in clinical studies, sulin-
dac caused adenoma regression in FAP patients without affecting
proliferation in rectal mucosa (66). Although these findings do
not exclude potential antiproliferative effects in adenomas, sulin-
dac sulfone was also shown to lack antiproliferative activity in
colorectal polyps of FAP patients (53). Conversely, other clinical
studies indicate that celecoxib can decrease proliferation rates in
adenomas from FAP patients (132) as well as in the bronchial
epithelium of former smokers (133). Animal studies support
these observations by providing evidence that various NSAIDs,
including sulindac sulfide, can decrease proliferation rates in
tumors from carcinogen-treated rats (69) and in APC∆716 mice
(134). Indeed, aspirin, sodium salicylate, sulindac sulfide, sulin-
dac sulfone, indomethacin, celecoxib, and piroxicam have all been
reported to inhibit cell cycle progression in vitro by inducing a
G0/G1 cell cycle arrest (2).
Transitions between different phases of the cell cycle are con-
trolled by various cyclins, cyclin-dependent kinases (CDKs), and
CDK inhibitors. Studies from our lab have shown that direct
inhibition of PDE5 by sulindac sulfide can downregulate the
expression level of G1/S transition-specific cyclin D1 in breast
cancer cell lines (61). More recent results extend these find-
ings into colorectal adenoma and carcinoma cell lines suggest-
ing that PDE5 inhibition can directly attenuate proliferation in
tumor cell lines (135). Since cyclin D1 is a target gene for the β-
catenin/TCF-Lef complex, the proposed mechanism of cyclin D1
downregulation was shown to involve elevation of cGMP, activa-
tion of PKG, and subsequent attenuation of nuclear β-catenin
levels via proteasomal degradation and transcriptional inhibi-
tion (Figure 5). Previously, sulindac sulfone and its analogs with
improved PDE5 inhibition were also shown to downregulate cyclin
D1 levels (136), suggesting that the ability to block cell cycle
progression by sulindac metabolites is COX-independent and at
least partially mediated through PDE5 inhibition. Another target
gene of the APC/β-catenin pathway important for cellular pro-
liferation is the c-myc oncogene, which upregulates cyclins but
downregulates p21. Therefore, it is logical to suggest that inhi-
bition of c-myc expression by targeting PDE5 is an additional
mechanism by which sulindac can reduce tumor cell prolifera-
tion. Importantly, upregulation of the CDK inhibitor p21waf1, but
not p27kip1, was established to be required for the in vivo effi-
cacy of sulindac by the finding that tumors in APC1638N mice
with p21 inactivation (APC+/−, p21+/− or−/− mice) were unre-
sponsive to sulindac treatment (137–139). Later studies demon-
strated that the induction of p21 and inhibition of proliferation
after sulindac treatment, in vitro and in vivo, was dependent on
the expression of JNK1 (84). These findings provide a poten-
tial link between the activation of PKG by sulindac metabolites
and the induction of cell cycle arrest via consequent upregula-
tion of JNK1 and p21. Other studies have shown that p21waf1
upregulation by sulindac treatment is partially mediated through
the COOH-terminal Src kinase (Csk), pointing to the involve-
ment of Csk/Src pathway in the antiproliferative effects of sulindac
(140).
FIGURE 5 | Chemical structures of non-COX-inhibitory derivatives of
sulindac and celecoxib.
The G1-phase cell cycle arrest induced by celecoxib treatment
in multiple tumor cell lines is accompanied by decreased expres-
sion of cyclins A, B, and D; and increased expression of cell
cycle inhibitors p21waf1 and p27kip1 (141–143). One of the tar-
gets that can mediate these effects is proposed to be protein kinase
B (PKB/Akt) or its upstream kinase PDK-1. As mentioned pre-
viously, celecoxib and its COX-sparing analog OSU-03012, can
directly inhibit PDK-1 in an ATP-competitive manner thereby
blocking signaling through the downstream Akt pathway (111,
113). Akt acts a positive regulator of cell cycle progression by phos-
phorylating and inactivating CDK inhibitors p21waf1 and p27kip1.
This results in the activation of various cyclin-CDK complexes
leading to DNA replication and proliferation (144–146). There-
fore, inhibition of PDK-1/Akt signaling represents one mechanism
by which celecoxib induces a cell cycle block. Although sulindac
sulfide has been shown to inhibit Akt signaling by directly binding
RXR, it remains unclear whether its effects on p21 levels and cell
cycle progression are mediated through this pathway. However,
p21 induction by sulindac treatment is likely not mediated by p53,
the well-known positive regulator of p21, since p53 induction is
not a determinant of sensitivity to sulindac metabolites in colon
cancer cell lines (51).
It is tempting to suggest that inhibition of SERCA by celecoxib
and sulindac sulfide is an important mechanism responsible for
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the antiproliferative properties of these compounds. As a result of
ESR-mediated downregulation of general translation, short-lived
proteins, such as various cyclins, quickly disappear and cannot
be replenished. This leads to the loss of CDK activity for which
they are essential subunits. Consequently, CDK target proteins,
most notably the retinoblastoma (Rb) tumor-suppressor protein,
cannot be phosphorylated allowing them to remain active and
prevent cells from progressing toward the S phase. Although a
functional link is difficult to establish due to the presence of mul-
tiple upstream events, the effects of celecoxib and sulindac sulfide
on SERCA provide a plausible explanation for their effects on the
cell cycle.
Lastly, direct inhibition of IKKβ by aspirin, salicylate, and
sulindac may be another mechanism that could account for the
antiproliferative effects of these NSAIDs via downregulation of
NF-κB-mediated proliferative genes such as interleukin-2 (IL-2),
granulocyte-macrophage colony-stimulating factor (GM-CSF),
c-myc, cyclin D1, and COX-2, among others.
INHIBITION OF ANGIOGENESIS, TUMOR CELL INVASION,
AND METASTASIS
It is now well-established through a large body of evidence that
COX-2 derived eicosanoids (prostaglandins, thromboxanes, and
leukotrienes) contribute to tumor development through their role
in angiogenesis. COX-2 overexpression in tumor cells, surround-
ing stroma, and/or interstitial inflammatory cells (predominantly
macrophages) promotes tumor vascularization by inducing the
expression of vascular endothelial growth factor (VEGF) and
increasing endothelial cell proliferation and migration (25, 147,
148). Consequently, traditional NSAIDs as well as selective COX-
2 inhibitors have been shown to inhibit tumor growth through
antiangiogenic mechanisms in experimental models (148). How-
ever, several studies provide evidence that COX-independent
mechanisms may contribute to the antiangiogenic effects of
NSAIDs. For example, sulindac sulfone was found to inhibit
angiogenesis in intradermal lung tumor xenografts in mice (149),
in the ex vivo chick embryo chorioallontoic membrane (CAM)
assay (150, 151) and in an in vivo mouse corneal neovascular-
ization assay (152). It is important to note that the CAM and
corneal neovascularization assays represent non-inflammatory
angiogenesis models and hence, the efficacy of sulindac metabo-
lites points to an underlying mechanism unrelated to COX-2
inhibition.
As for potential alternative targets, it is plausible that cGMP
phosphodiesterase inhibition by these compounds and subsequent
activation of PKG is responsible for their antiangiogenic proper-
ties, given the ability of sulindac sulfone to inhibit angiogenesis.
In support of this possibility, studies by Browning et al. have
demonstrated that PKG overexpression in SW620 colon cancer
cells significantly inhibits angiogenesis and reduces VEGF lev-
els after subcutaneous implantation in mice (153). In addition,
ectopic PKG expression was shown to block hypoxic adaptation
in SW620 xenografts by inhibiting the transcriptional activity of
Hif-1α, a critical driver of VEGF expression and angiogenesis
(154). Although the mechanism of Hif-1α inhibition by PKG is
not fully elucidated, an earlier study by Kaidi et al. provides evi-
dence that β-catenin can enhance Hif-1-mediated transcription
through a direct binding interaction (155). In addition to these
findings, SW620 cells with PKG overexpression show reduced lev-
els of β-catenin compared with parental cells. Therefore, cGMP
PDEs represent potential targets that can mediate the antian-
giogenic properties of NSAIDs through attenuation of β-catenin
levels (Figure 5). It needs to be considered, however, that the
PDE5 inhibitors, sildenafil, and tadalafil, can promote angio-
genesis in various models of tissue damage and wound heal-
ing (156). Nonetheless, functional consequences of cGMP PDE
inhibition on angiogenesis are yet to be tested in neoplastic
models.
Studies using human PANC-1 pancreatic adenocarcinoma cell
lines indicate that the transcription factor Sp1 may have a direct
role in the inhibition of angiogenesis by celecoxib. Constitutive
activation of Sp1 is a crucial determinant of VEGF overexpres-
sion in pancreatic cancers. Wei et al. demonstrate that celecoxib
potently downregulates Sp1 protein levels and inhibits its trans-
activating activity in PANC-1 cells (157). By conducting deletion
and mutational analyses of the VEGF promoter, Sp1 binding sites
were shown to be required for celecoxib-mediated attenuation
of VEGF expression. In cell-free assays, celecoxib can inhibit the
DNA-binding ability of Sp1, suggesting a direct interaction may
be responsible for the effects of celecoxib on Sp1 activity. In addi-
tion, celecoxib, and other COX-2 inhibitors such as nimesulide and
NS-398 can induce proteasomal degradation of Sp1 and decrease
Sp1 phosphorylation, in multiple colon cancer cell lines, which is
required for its transcriptional activity (158). Although the pre-
cise mechanisms responsible for these effects remain unknown,
comparable responses were observed in COX-2-expressing and -
non-expressing cell lines, suggesting that mechanisms unrelated
to COX may be involved.
Evidence implicating a direct NSAID target in the Hif-
1α/VEGF-mediated angiogenic response in human tumors is thin.
As such, it needs to be considered that the antiangiogenic proper-
ties of NSAIDs can be secondary to their effects on endothelial cell
survival, proliferation, and/or migration. For example, inhibition
of angiogenesis by sulindac sulfide and sulfone in the CAM model
was paralleled by induction of apoptosis (150). Similarly, cele-
coxib and the COX-2-inactive analog, dimethyl-celecoxib (DMC),
were shown to inhibit the proliferation of human umbilical vein
endothelial cells (HUVEC) and display efficacy in the CAM model
at concentrations lower than those required to induce apopto-
sis (159). These effects were associated with the induction of a
G1-phase cell cycle arrest and inhibition of PDK-1/Akt signaling.
More recent studies implicate SERCA inhibition as a potential con-
tributor by showing that DMC causes ESR-mediated cell death in
tumor-associated brain endothelial cells (TuBECs) (160). As sup-
port for this possibility, Neiderberger et al. reported that celecoxib-
induced cell death in HUVEC cells is accompanied by elevation
of intracellular Ca+2 and activation of caspases (161). In addi-
tion, rofecoxib was unable to induce apoptosis in HUVECs indi-
cating the involvement of a celecoxib-specific COX-independent
target.
Matrix metalloproteases (MMPs) represent another class of
major contributors to angiogenesis and invasion that are inhib-
ited by NSAID treatment. MMPs 2 and 9 are the principal
enzymes involved in degrading type IV collagen of the basement
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membrane allowing endothelial cells to reach incipient tumors or
cancer cells to invade adjacent tissue leading to metastases (162).
In U87 MG human glioblastoma cell lines, celecoxib (40µM),
sulindac (300µM), sulindac sulfide (150µM), and sulindac sul-
fone (400µM) have been shown to inhibit invasion through
downregulation of MMPs 2 and 9 (163). This anti-invasive activity
could be abrogated by overexpression of phosphorylated Akt using
a Myr-Akt vector or potentiated through the use of a dominant-
negative Akt (DN-Akt) vector. Furthermore, downregulation of
MMP levels was found to be due to the inhibition of Akt-mediated
transcription in glioblastoma cell lines. Although these findings do
not provide a definitive target, it can be postulated that celecoxib,
through its direct inhibition of PDK-1, and sulindac, via its inter-
action with RXRα, are able to downregulate Akt-dependent tumor
cell invasion. Intriguingly, NSAIDs that have not been previously
reported to inhibit Akt signaling such as aspirin, ketoprofen, and
naproxen were found to lack anti-invasive properties in these cell
lines.
Finally, a recent report by Li et al. provides evidence that sulin-
dac sulfide (50µM) can inhibit tumor cell invasion by suppressing
Nf-κB-mediated transcription of microRNAs in human colon and
breast cancer cell lines (164). The majority of microRNAs modu-
lated by sulindac sulfide treatment were found to contain Nf-κB
binding sites in their promoter regions. In addition, Nf-κB could
be isolated from the promoters of several microRNAs, such as miR-
10b, downregulated by sulindac sulfide treatment and previously
shown to have a role in tumor cell invasion. Furthermore, sulin-
dac sulfide was able to significantly block the invasion stimulated
by the overexpression of these microRNAs. Notably, anti-invasive
activity was observed at concentrations lower than those required
to significantly inhibit the growth of these cell lines, which sug-
gests potential benefits for preventing metastasis in patients at risk
of disease progression. These effects were associated with inhibi-
tion of IKKβ and IκB phosphorylation, and attenuation of nuclear
Nf-κB levels. Although it is unclear whether these effects are medi-
ated by direct IKKβ binding, this study establishes a mechanistic
link between inhibition of Nf-κB signaling by sulindac and its
anti-invasive effects via microRNA modulation. Future studies are
warranted to test whether aspirin and/or salicylate can replicate
these effects since IKKβ is a direct target of these compounds.
INDUCTION OF AUTOPHAGY
Autophagy is a catabolic process whereby cells degrade cyto-
plasmic components in lysosomes. This process is crucial for
maintaining cellular homeostasis by removing damaged proteins
and organelles, eliminating invading pathogens, and recycling
cellular building blocks thereby providing substrates for energy
generation. In the past decade, multiple studies have provided
genetic and functional links between impaired autophagy and can-
cer suggesting that autophagy can serve as a tumor-suppressor
mechanism. Conversely, consistent with its role in damage miti-
gation, autophagy has been demonstrated to promote growth of
established tumors under conditions of hypoxia, and in response
to chemo- or radio-therapy. In certain cases, autophagy has
also been shown to mediate cell death either directly through
excessive degradation of the cytoplasm or selective digestion of
vital organelles such as mitochondria, or indirectly via triggering
apoptosis. Excellent reviews on the role of autophagy in cancer
have been previously published (165–167).
Regarding NSAID chemoprevention, a growing number of
studies report that various NSAIDs and/or NSAID analogs can
induce autophagy in tumor cell lines. An interesting connection
between aspirin and autophagy was established in a recent report
by Din et al. who showed that aspirin (5 mM) can inhibit
Akt/mTOR signaling, activate AMP-activated kinase (AMPK), and
induce autophagy in multiple colon tumor cell lines, in mice, and
in the rectal mucosa of patients on a daily aspirin regimen. Acti-
vation of AMPK by aspirin was found to be comparable to that
produced by known activators of this kinase, phenformin and
metformin. An independent study by Hawley and colleagues con-
comitantly showed that AMPK is a direct molecular target of sali-
cylate, the active metabolite of aspirin using purified kinase assays
(168). These findings are important in the context of numerous
epidemiologic, clinical, and experimental studies which indicate
that use of metformin, a commonly prescribed antidiabetic drug,
is associated with reduced cancer incidence and mortality (169,
170). Furthermore, its antineoplastic activity has been attributed
to activation of AMPK and subsequent inhibition of mTOR activ-
ity, which among others, results in induction of autophagy (171,
172). Therefore, it is reasonable to suggest that activation of AMPK
and subsequent autophagy induction by aspirin may contribute to
its chemopreventive effects.
Another report demonstrates that sulindac sulfide can induce
autophagy, followed by cell death, in gastric cancer cells at phys-
iologically relevant concentrations (10µM) (173). Tumor cell
death was found to be dependent on downregulation of survivin,
which could be abrogated by siRNA knockdown of the essential
autophagy protein LC3. These results suggest that survivin may
be selectively degraded by autophagic vacuoles after sulindac sul-
fide treatment. As such, sulindac sulfide-induced autophagy may
function as an intermediate process that enables later apoptotic
events by preventing the accumulation of an anti-apoptotic pro-
tein. As evidence for a COX-independent mechanism, we have
recently reported that a novel non-COX-inhibitory sulindac deriv-
ative, sulindac sulfide amide (SSA), inhibits the growth of human
lung adenocarcinoma cell lines primarily through the induction of
autophagy (174). SSA also induced apoptosis, albeit at concentra-
tions appreciably higher than its IC50 value for growth inhibition.
Nonetheless, treatment with pan-caspase inhibitor z-VAD-FMK
could not prevent cell death, whereas suppressing autophagy by
Atg7 siRNA could significantly increase cell viability after SSA
treatment. Furthermore, the induction of autophagy and loss of
cell viability was found to be mediated by Akt/mTOR inhibition
and could be partially blocked by the overexpression of activated
Akt via a Myr-Akt plasmid. On the other hand, sulindac sul-
fide only induced autophagy at concentrations higher than those
required to inhibit tumor cell growth and apoptosis appeared to
be the primary mechanism of cell death. These findings suggest
that SSA and sulindac sulfide may share similar targets that ulti-
mately lead to autophagy induction, but that SSA represents a
much more potent inducer of autophagy than the COX-inhibitory
sulfide metabolite of sulindac. The in vivo relevance of the induc-
tion of cell death through autophagy by SSA is still untested, but
remains an interesting possibility to explain its tumor-selective
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effects and strong antitumor efficacy as reported in the human
HT-29 xenograft mouse model (175). Together, these findings pro-
vide proof-of-concept evidence that COX-independent targets of
sulindac and possibly other NSAIDs are relevant for the induc-
tion of autophagy. As such, celecoxib and its non-COX-inhibitory
analog, OSU-03012, are the only NSAIDs known to directly target
a negative regulator of autophagy signaling, PDK-1. Nonetheless,
the relevance of PDK-1/Akt inhibition in autophagy induction by
these compounds is unclear since OSU-03012 has previously been
shown to induce autophagy and cell death without affecting Akt
phosphorylation (176).
Altogether, the amount of data providing a mechanistic under-
standing of the precise role of autophagy after NSAID treat-
ment is sparse. Studies described above suggest that induction of
autophagy may contribute to the chemopreventive properties of
NSAIDs. However, several other studies demonstrate that upregu-
lation of autophagy by NSAID treatment can delay or inhibit apop-
tosis induction in tumor cell lines (177, 178). The most accurate
approach for assessing the role of autophagy in NSAID chemo-
prevention would be a tumorigenesis model, whereas experiments
in cell culture or on established xenograft tumors might reflect
conditions in which autophagy will serve to counteract NSAID
cytotoxicity. Functional evidence linking autophagy induction
and inhibition of tumor formation by NSAIDs in genetic or
carcinogen-induced animal models of tumorigenesis is lacking.
In order to conclusively answer this question, new mouse strains
that harbor mutations in both a tumor-suppressor gene and
an autophagy gene such as APCMin/+, ATG5−/− or APCMin/+,
Beclin−/+ mice need to be generated.
CONCLUSION AND FUTURE DIRECTIONS
Studies of the pathways by which NSAIDs inhibit carcinogenesis
have not provided conclusive evidence of the molecular targets
that are clinically relevant to their chemopreventive activity. Evi-
dence described above provides a strong case that inhibition of
COX enzymes cannot explain the complex antineoplastic activ-
ity of NSAIDs. Identification of COX-independent targets and
mechanisms most important for the antineoplastic properties of
these drugs can be used to develop more efficacious chemopreven-
tive drugs without the gastrointestinal, renal, and cardiovascular
side effects associated with NSAIDs and COX-2 inhibitors. Cur-
rently, sulindac derivatives have been developed that inhibit PDE5
and have antitumor activity without inhibiting COX-1 or COX-2
(179). These experimental agents demonstrate the feasibility of
developing safer and more efficacious drugs for chemoprevention
by targeting PDE5. Furthermore, the sulindac derivative K-80003
that has been designed to selectively target RXRα and celecoxib
derivatives developed to inhibit PDK-1 without COX-inhibition
represent other examples of separating COX-inhibitory activity
and antitumor efficacy. Previously published non-COX-inhibitory
derivatives of sulindac and celecoxib are shown in Figure 5.
It needs to be stated that most of the studies described in this
review were performed using human cancer cell lines and their
in vivo significance is yet to be determined. The concentrations of
NSAIDs used in cell culture experiments often significantly exceed
maximum plasma levels that can be achieved in patients in clin-
ical studies. However, despite relatively low blood levels, NSAIDs
are able to achieve efficacy in vivo while these concentrations are
not sufficient to inhibit tumor cell growth in vitro. This apparent
discrepancy suggests that the in vivo response to NSAID therapy
may reflect accumulative effects in tissues as a result of chronic
administration to patients. Indeed, there is evidence that colonic
epithelial cells are exposed to much higher concentrations of sulin-
dac sulfide than those detected in plasma, owing to its unique
metabolism by colonic bacteria (180–182). Other studies show
that antiproliferative activity can be achieved in vitro at clinically
relevant concentrations by increasing the duration of treatment.
For example, Patel et al. have reported that low-dose (2.5–10µM)
celecoxib treatment can inhibit the growth of COX-2-negative
PC-3 and LNCAP human prostate cancer cell lines when treat-
ment period is extended to 96 h (183). Altogether, these findings
highlight the need for more detailed studies on tissue pharmaco-
kinetics and tumor uptake of various NSAIDs. In this respect, it is
possible that dose-limiting toxicities from COX-inhibition prevent
complete response during NSAID therapy and lead to a pharma-
codynamic mechanism of resistance, which can be overcome by
the optimization of non-COX targets.
Given the complexity and the multitude of pathways that medi-
ate the biochemical effects of NSAIDs, it is highly challenging
to identify relevant targets suitable for cancer chemoprevention.
Treatment with a single drug can lead to pleiotropic effects by
targeting multiple cellular molecules and pathways, while specific
targeting of a single molecule can also induce a wide variety of
changes in cellular functions. Therefore, it will be useful to con-
sider targeting pathways that show a higher apoptosis-inducing
or antiproliferative activity with the least potential for off-target
effects. In addition to tissue culture studies, it is crucial to val-
idate the in vivo roles of candidate targets of chemoprevention
in experimental animal studies for an accurate assessment of
efficacy and toxicity. Further elucidation of COX-independent
NSAID targets has the potential to contribute to future chemo-
preventive strategies by enabling identification of novel agents
and/or driving rational modification of existing chemopreventive
drugs.
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